Novavax (NVAX)
NASDAQ:NVAX
Want to see NVAX full AI Analyst Report?
NVAX Stock Chart & Stats
$8.84
-$1.22(-11.32%)
At close: 4:00 PM EST
$8.84
-$1.22(-11.32%)
Day’s Range― - ―
52-Week Range$6.13 - $11.97
Previous CloseN/A
Volume4.15M
Average Volume (3M)5.53M
Market Cap
$1.68B
Enterprise Value$1.87B
Total Cash (Recent Filing)$790.33M
Total Debt (Recent Filing)$295.06M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 12, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding164,438,130
10 Day Avg. Volume5,809,520
30 Day Avg. Volume5,532,686
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit3.71
Enterprise Value/Ebitda-32.81
Forecast
1Y Price Target
$11.60Price Target Upside31.22% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$409.97M
Bulls Say, Bears Say
Bulls Say
Strategic PartnershipsNovavax’s expanding partner network (Pfizer, Sanofi and several MTAs) diversifies commercialization routes and validates Matrix‑M adoption. Durable alliances create pathways for milestone and royalty income, reduce sole reliance on direct sales, and scale reach via partner capabilities over the medium term.
Partner-driven Revenue GrowthMaterial YoY gains in supply sales and licensing indicate partner monetization is becoming a consistent revenue engine. If sustained, partner-derived supply contracts and royalties provide higher-margin, repeatable cash flows that stabilize topline variability and support reinvestment in R&D without depending solely on direct vaccine sales.
Cash Runway & Non-dilutive FundingSignificant cash, accounts receivable and recent nondilutive inflows plus credit access provide a multi-year runway into 2028, reducing near-term refinancing pressure. This liquidity supports prioritized IND-enabling work, partnership execution and expense restructuring, improving the company’s ability to reach breakeven if milestones materialize.
Bears Say
Negative Shareholders' EquityConsistently negative shareholders’ equity reflects structural balance sheet weakness that limits financial flexibility. Negative equity reduces solvency cushions, complicates borrowing terms and increases the risk of dilutive financing if performance falters, constraining strategic optionality and partner/lender confidence over time.
Persistent Cash BurnNegative trailing operating and free cash flows show the company is consuming cash rather than generating it, making operations reliant on external funding or partner receipts. Continued cash burn narrows runway if partner milestones miss expectations and increases the likelihood of future dilution or constrained R&D investment.
Dependence On MTA-to-License ConversionsRevenue and milestone visibility hinge on partners converting MTAs into licenses; timelines are uncertain and driven by external clinical and commercial decisions. This dependency creates structural timing and execution risk—delays or non‑conversion can materially postpone expected royalties and payments, impacting long-term cash flow planning.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $6.13 and its highest was $11.97 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.68B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 12, 2026 which is in 67 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 06, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.182.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.4.
How many shares outstanding does Novavax have?
Novavax has 164,438,130 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went up 15.556%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.60 (31.22% Upside)
$11.60 (31.22% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.76%
12-Months-Change
Fundamentals
Return on Equity
89.73%
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$11.60
▲(31.22% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Ownership Overview
0.51% Insiders
12.64% Mutual Funds
20.44% Other Institutional Investors
47.62% Public Companies and
Individual Investors